(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.80%) $83.18
(1.14%) $1.945
(-0.28%) $2 340.70
(0.11%) $27.57
(0.66%) $928.20
(-0.27%) $0.932
(-0.32%) $10.99
(-0.35%) $0.798
(0.25%) $92.11
-0.09% $ 273.05
Live Chart Being Loaded With Signals
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally...
Stats | |
---|---|
Tagesvolumen | 164 583 |
Durchschnittsvolumen | 725 457 |
Marktkapitalisierung | 131.95B |
EPS | $0 ( 2024-02-13 ) |
Last Dividend | $1.621 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.83 |
ATR14 | $0.0970 (0.04%) |
Volumen Korrelation
CSL Ltd Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
CSL Ltd Korrelation - Währung/Rohstoff
CSL Ltd Finanzdaten
Annual | 2023 |
Umsatz: | $19.59B |
Bruttogewinn: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2023 |
Umsatz: | $19.59B |
Bruttogewinn: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2022 |
Umsatz: | $14.47B |
Bruttogewinn: | $7.68B (53.05 %) |
EPS: | $6.63 |
FY | 2021 |
Umsatz: | $10.27B |
Bruttogewinn: | $5.80B (56.49 %) |
EPS: | $5.22 |
Financial Reports:
No articles found.
CSL Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.758 (N/A) |
$0 (N/A) |
$1.621 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0167 | 1994-11-08 |
Last Dividend | $1.621 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $28.07 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.48 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.26 | |
Div. Directional Score | 9.64 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LBL.AX | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
STO.AX | Ex Dividend Knight | 2023-08-28 | Semi-Annually | 0 | 0.00% | |
COS.AX | Ex Dividend Knight | 2023-10-19 | Semi-Annually | 0 | 0.00% | |
MYS.AX | Ex Dividend Junior | 2023-08-23 | Annually | 0 | 0.00% | |
WGB.AX | Ex Dividend Junior | 2023-10-12 | Semi-Annually | 0 | 0.00% | |
ENN.AX | No Dividend Player | 2023-06-29 | Annually | 0 | 0.00% | |
PE1.AX | Ex Dividend Junior | 2023-07-03 | Semi-Annually | 0 | 0.00% | |
AMH.AX | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
GWA.AX | Ex Dividend Knight | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
RHI.AX | No Dividend Player | 2023-07-10 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.180 | 1.500 | 6.41 | 9.61 | [0 - 0.5] |
returnOnAssetsTTM | 0.0696 | 1.200 | 7.68 | 9.21 | [0 - 0.3] |
returnOnEquityTTM | 0.156 | 1.500 | 9.38 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.450 | -1.000 | 5.50 | -5.50 | [0 - 1] |
currentRatioTTM | 2.15 | 0.800 | 4.25 | 3.40 | [1 - 3] |
quickRatioTTM | 0.971 | 0.800 | 9.00 | 7.20 | [0.8 - 2.5] |
cashRatioTTM | 0.216 | 1.500 | 9.91 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.282 | -1.500 | 5.30 | -7.95 | [0 - 0.6] |
interestCoverageTTM | 6.97 | 1.000 | 8.53 | 8.53 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.484 | 1.000 | 5.26 | 5.26 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.244 | 1.000 | 7.12 | 7.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.261 | 1.000 | 9.66 | 9.66 | [0.2 - 2] |
assetTurnoverTTM | 0.388 | 0.800 | -0.748 | -0.599 | [0.5 - 2] |
Total Score | 12.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.66 | 1.000 | 6.60 | 0 | [1 - 100] |
returnOnEquityTTM | 0.156 | 2.50 | 9.60 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.80 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.393 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.450 | 1.500 | 5.50 | -5.50 | [0 - 1] |
pegRatioTTM | 7.92 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.75 | 0 | [0.1 - 0.5] |
Total Score | 7.26 |
CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.